Lobbying Relationship

Client

BioMarin Pharmaceutical, Inc.

More records

Lobbying firm

VENN STRATEGIES

More records

  • Orphan drugs and rare diseases, matters related to drug reimbursement policy.
  • Orphan drugs and rare disease matters

Duration: to

General Issues: Health Issues, Taxation/Internal Revenue Code

Spending: about $490,000 (But it's complicated. Here's why.)

Agencies lobbied since 2013: U.S. Senate, House of Representatives, Food & Drug Administration (FDA), U.S. Senate,

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Jack Baer Legislative Assistant for Congressman Chip Cravaack (R-MN) Legislative Assistant-Congressman Chip Cravaack
Lindsay Punzenberger Legislative Assistant for Congressman Thomas E. Petri (R-WI)
Noelle Lundberg Legislative Director for Chairman Bill Archer (R-TX) Legislative Director - Chairman Bill Archer
Tim Carey Legislative Director for Representative Brad Sherman (D-CA) Legislative Director for U.S. Representative Brad Sherman (D-CA), Deputy Legislative Director for Representative Anna G. Eshoo (D-CA Legislative Director-Rep Brad Sherman Legislative Director - Rep Brad Sherman
Elizabeth Lee Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin
Michael Spira Chief of Staff for former Congresswoman Carolyn McCarthy (D-NY) and Deputy Chief of Staff for Congressman Ed Perlmutter (D-CO)
Jessica Layson Davis Legislative Director for Rep. Austin Scott (R-GA)
Brian Beaty staff for Sen. Mark Warner (D-VA) staff of Sen. Mark Warner (D-VA)
Thomas Garrigan Associate Legislative Asst for Sen.Sheldon Whitehouse (D-RI)
Jessica Layson Legislative Director for Rep. Austin Scott (R-GA)
Stephanie Silverman n/a
Amy Redl n/a
Elizabeth Brooks n/a
Lauren Reliford n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Termination
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Amendment
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page